Clinical Trial Search

Primary: Change From Baseline to End of Treatment Period I in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -10.1; -14.4; -12.6 units on a scale — p=0.034

Primary: Change From Baseline to Endpoint of 12 Weeks in the 3-day Average of Awake Time Per Day Spent in the "Off" State — -0.4; -1.3; -1.6; -1.7 hours/day — p=0.753

Primary: Percentage of Participants With Intra-operative Hemostasis at the Evaluation Site Within 3 Minutes After Application of the Randomized Treatment — 26.0; 18.0 percentage…

Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 8; 1 participants — p=<0.001

Primary: Injection Site Adverse Events (Following Injection) — 138; 141; 126; 146 Adverse events — p=0.475

Primary: Airway Seal Pressure After Device Placement — 28; 27; 24 cmH2O

Primary: Change in Symptom and Problem Severity — 22; 13 units on a scale

Primary: Number of Participants With Intracranial Bleeding and/or Recurrent Ischemic Lesion as Confirmed by MRI Imaging — 47; 48 Participants

Primary: Percent Reduction in Oxygen Requirement From Baseline — 5.4; 16.5 percentage FiO2

Primary: Percentage of Participants With > 30% Reduction From Baseline in Mean Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority Analysis — 63.9; 77.9…

Primary: Change in Mean Days of Any Substance Use for Women — -3.93; -1.74; -4.45; 0.60 Days of any substance use per month — p=<0.05

Primary: Scale of Prodromal Symptoms (SOPS) Negative Scale — 7.6; 11.3 SOPS negative final score — p=0.03

Primary: Survival Free of Atrial Fibrillation — 28; 31 participants

Primary: Grasp Release Test - Test of Functional Ability to Pick up and Move Objects — 2; 5.5 Number of Completions

Primary: Proportion of Subjects Achieving Hemostasis by Four Minutes After Treatment Start — 92.8; 80.5 Percent of subjects achieving hemostasis